Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 18/20 | 0.56 |
| ▸ | HTR2A | P28223 | 13/20 | 0.56 |
| ▸ | HTR1A | P08908 | 11/20 | 0.56 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055026 | 1.00 | DRD3 (0.60) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL12930984 | 1.00 | DRD3 (0.60) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL12930983 | 0.99 | DRD3 (0.61) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL12930982 | 0.97 | DRD3 (0.62) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL1055778 | 0.95 | DRD3 (0.63) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL1055174 | 0.93 | DRD3 (0.60) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL826019 | 0.92 | DRD3 (0.62) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL12931015 | 0.92 | DRD3 (0.61) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL826012 | 0.92 | DRD3 (0.63) | DRD3DRD2HTR2AHTR1AKCNH2 | |
| SCHEMBL12930981 | 0.92 | DRD3 (0.65) | DRD3DRD2HTR2AHTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-07-28 | — | — | US | disclosed |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-10-01 | — | — | US | disclosed |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2019-01-31 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LTD (IE) | 2015-12-31 | — | — | US | disclosed |
| US-9102618-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-07 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376143-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-20140221653-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | SI, NAAA, NIT2 | DRD3 4303/4885DRD2 4366/4885HTR2A 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.